

Rhythm Pharmaceuticals, Inc. (RYTM)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001649904

Rhythm Pharmaceuticals, Inc. RYTM; healthcare	
Grade	A/B A B C D E on the A/B boundary of 371 graded peers percentile 22.4; sampling error 2.5 points; lower is stronger
Rank	84 of 371
Profitability	B/C percentile 40.5
Solvency	C percentile 45.2
Growth and financing	B percentile 29.6
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$480.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$89.61 2026-10-08; market equity \$6.2B
Price used in grade	None



A/B, the bull
on the A/B boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: B from Sep 30, 2026, A/B from Oct 3, 2026, B from Oct 7, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 40.5						
Gross profitability		35.5%	32.2%	38.5	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(18.5%)	(6.6%)	23.5	811	2025-12-31
Gross margin stability, five years		3.6 pts	2.8 pts	59.5	243	2025-12-31
Solvency, sleeve percentile 45.2						
Twelve-month failure probability		0.06%	0.07%	38.9	248	2026-06-30
Altman Z double-prime		(6.24)	(0.31)	55.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.41x	2.96x	41.6	839	2025-12-31
Growth and financing, sleeve percentile 29.6						
Revenue growth, three-year compound		100.2%	10.0%	5.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 8
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		7.9%	2.1%	34.9	704	2025-12-31
Net share issuance, one year		8.0%	2.5%	48.5	634	2026-02-24

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
79	Rigel Pharmaceuticals Inc. (RIGL)	21.1	A/B	
80	Axsome Therapeutics, Inc. (AXSM)	21.4	A/B	
81	Axogen, Inc. (AXGN)	21.6	A/B	
82	Halozyme Therapeutics, Inc. (HALO)	21.9	A/B	
83	4D Molecular Therapeutics, Inc. (FDMT)	22.2	A/B	dilution, short runway
84	Rhythm Pharmaceuticals, Inc. (RYTM) <	22.4	A/B	
85	Puma Biotechnology, Inc. (PBYI)	22.7	B	fortress balance sheet
86	Warby Parker Inc. (WRBY)	23.0	B	
87	Cronos Group Inc. (CRON)	23.2	B	
88	Guardant Health, Inc. (GH)	23.5	B	
89	Avalo Therapeutics, Inc. (AVTX)	23.8	B	dilution, degenerate inputs

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	5.1%	8.0%	48
Distance from 52-week high	(23.8%)	(31.4%)	60
EBIT to enterprise value	(3.1%)	(1.5%)	45
Free cash flow yield	(1.9%)	(1.0%)	48
Book value to price	0.02	0.28	14
Sales to price	0.03	0.31	10
Composite equity issuance, five years	31.6%	20.3%	59
Relative strength against the sector, log excess return	(0.16)	(0.14)	48

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$65.6M
Operating cash flow, four quarters	-\$105.3M
Months of runway	7.5
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$61.9M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$189.8M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$19.5M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
3	assets	us-gaap:Assets	\$480.2M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
4	net income	us-gaap:NetIncomeLoss	-\$196.5M	2025-12-31	2026-02-26	10-K	0001628280-26-012399

5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$115.7M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
6	assets	us-gaap:Assets	\$392.3M	2024-12-31	2026-02-26	10-K	0001628280-26-012399
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$130.1M	2024-12-31	2026-02-26	10-K	0001628280-26-012399
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$13.4M	2024-12-31	2026-02-26	10-K	0001628280-26-012399
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$77.4M	2023-12-31	2026-02-26	10-K	0001628280-26-012399
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$9.3M	2023-12-31	2026-02-26	10-K	0001628280-26-012399
11	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$23.6M	2022-12-31	2024-02-29	10-K	0001558370-24-002181
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$2.1M	2022-12-31	2025-02-28	10-K	0001558370-25-001889
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$3.2M	2021-12-31	2024-02-29	10-K	0001558370-24-002181
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$599,000	2021-12-31	2024-02-29	10-K	0001558370-24-002181
15	current assets	us-gaap:AssetsCurrent	\$466.9M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
16	current liabilities	us-gaap:LiabilitiesCurrent	\$105.9M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.4B	2025-12-31	2026-02-26	10-K	0001628280-26-012399
18	operating income	us-gaap:OperatingIncomeLoss	-\$192.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
19	book equity	us-gaap:StockholdersEquity	\$139.1M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
20	liabilities	us-gaap:Liabilities	\$210.2M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
21	operating income	us-gaap:OperatingIncomeLoss	-\$184.4M	2023-12-31	2026-02-26	10-K	0001628280-26-012399
22	interest expense	us-gaap:InterestExpense	\$13.9M	2023-12-31	2024-02-29	10-K	0001558370-24-002181
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$953,000	2025-12-31	2026-02-26	10-K	0001628280-26-012399
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$500,000	2025-12-31	2026-02-26	10-K	0001628280-26-012399
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$196.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012399
26	income tax	us-gaap:IncomeTaxExpenseBenefit	\$497,000	2025-12-31	2026-02-26	10-K	0001628280-26-012399
27	current assets	us-gaap:AssetsCurrent	\$374.2M	2024-12-31	2026-02-26	10-K	0001628280-26-012399
28	current liabilities	us-gaap:LiabilitiesCurrent	\$115.5M	2024-12-31	2026-02-26	10-K	0001628280-26-012399
29	assets	us-gaap:Assets	\$332.7M	2023-12-31	2025-02-28	10-K	0001558370-25-001889
30	assets	us-gaap:Assets	\$382.5M	2022-12-31	2024-02-29	10-K	0001558370-24-002181
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,285,039	2026-02-24	2026-02-26	10-K	0001628280-26-012399
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,223,727	2025-02-24	2025-02-28	10-K	0001558370-25-001889